Merck & Co., Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
Merck & Co., Inc. (MRK) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $23.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2014-02-27
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2013 was $23.00M, a 130.00% increase from fiscal 2012.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2012 was $10.00M.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2011 was -$5.00M.
- Merck & Co., Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2010 was -$11.00M, a 135.48% decline from fiscal 2009.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month as first filed |
|---|---|---|
| 2013-12-31 | $23.00M 10-K · filed 2014-02-27 | |
| 2012-12-31 | $10.00M 10-K · filed 2014-02-27 | -$10.00M 10-K · filed 2013-02-28 |
| 2011-12-31 | -$5.00M 10-K · filed 2014-02-27 | |
| 2010-12-31 | -$11.00M 10-K · filed 2013-02-28 | $11.00M 10-K · filed 2011-02-28 |
| 2009-12-31 | $31.00M 10-K · filed 2012-02-28 | |
| 2008-12-31 | -$79.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |